Japan's National Cancer Center (NCC) has initiated a nationwide clinical trial network known as LC-SCRUM-CD (Lung Cancer Genome Screening Project for Individualized Medicine – Clinical Development) to advance precision medicine in cancer treatment and research.
Collaborative Effort
This collaborative effort involves the NCC, Precision Medicine Asia Co., Ltd. (PREMIA), and Paradigm Health Inc. (Paradigm). The network builds upon the existing LC-SCRUM-Asia, which includes over 150 hospitals with extensive cancer genomic screening capabilities. The goal is to drive clinical trials that tailor treatments to individual patients based on their genetic makeup.
Roles and Responsibilities
National Cancer Center Hospital East (NCCHE) will play a crucial role in the network, leveraging its expertise in clinical trials. PREMIA will manage the network's data platform, integrating genetic and clinical data to identify potential clinical trial candidates efficiently.
Paradigm Health's Contribution
Paradigm Health will contribute its end-to-end clinical trial platform, designed to streamline clinical trial processes, reduce the burden on physicians and hospital staff, and expand patient trial access. Paradigm’s experience in working with rural and community-based health systems in the US will inform the design and operation of LC-SCRUM-CD, ensuring broader reach and accessibility.
Expected Benefits
The LC-SCRUM-CD network aims to increase efficiency for pharmaceutical companies conducting clinical trials in Japan, expand patient access to clinical trial options, reduce the time and burden on clinical staff, and improve patient outcomes through precision medicine.
Dr. Goto, deputy director and chief of the department of thoracic oncology at NCCHE and representative of LC-SCRUM-Asia, stated, "Working with our partners at PREMIA and Paradigm, we will fully utilize this expertise in clinical trial operations, allowing all patients who are taking part in LC-SCRUM-Asia to benefit from personalized access to the breadth of clinical trials being run by global biopharmaceutical sponsors at the same time as the US."
